Cel Sci (CVM) EBIT (2010 - 2026)
Cel Sci (CVM) posted EBIT of -$5.3 million for Q1 2026, up 0.8% sequentially from -$5.4 million in Q4 2025, and up 16.7% YoY from -$4.6 million in Q1 2025.
Cel Sci (CVM) EBIT (2010 - 2026) Analysis & Trends
Cel Sci has reported EBIT for 17 years, with the latest figure at -$5.3 million in Q1 2026.
- Quarterly EBIT rose 16.7% year-over-year to -$5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.2 million (up 14.81% YoY) and the FY2025 annual result came in at -$24.8 million, up 5.85% from the prior year.
- EBIT improved to -$5.3 million in Q1 2026 per CVM's latest filing, from -$5.4 million in the prior quarter.
- Over five years, EBIT peaked at -$5.3 million in Q1 2026 and troughed at -$9.6 million in Q1 2022.
- A 5-year average of -$7.1 million and a median of -$6.9 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2025: EBIT slipped 11.94% in 2022, then climbed 22.12% in 2025.
- Over 5 years, EBIT stood at -$7.7 million in 2022, then gained by 15.22% to -$6.5 million in 2023, then retreated by 6.28% to -$6.9 million in 2024, then gained by 22.12% to -$5.4 million in 2025, then gained by 0.8% to -$5.3 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$5.3 million, -$5.4 million, and -$6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.53 Bn | 130.68 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.34 Bn | 78.35 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.67 Bn | 59.48 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.94 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.78 Bn | 27.47 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.81 Bn | 9.42 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.21 Bn | 26.05 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 26.99 Bn | 26.15 Bn | - | 133.12 Mn |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - | -5.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.33 Mn |
| Dec 31, 2025 | -5.37 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -5.49 Mn |
| Mar 31, 2025 | -6.39 Mn |
| Dec 31, 2024 | -6.89 Mn |
| Sep 30, 2024 | -6.12 Mn |
| Jun 30, 2024 | -6.67 Mn |
| Mar 31, 2024 | -7.08 Mn |
| Dec 31, 2023 | -6.49 Mn |
| Sep 30, 2023 | -7.47 Mn |
| Jun 30, 2023 | -8.18 Mn |
| Mar 31, 2023 | -8.18 Mn |
| Dec 31, 2022 | -7.65 Mn |
| Sep 30, 2022 | -8.95 Mn |
| Jun 30, 2022 | -8.72 Mn |
| Mar 31, 2022 | -9.55 Mn |
| Dec 31, 2021 | -8.84 Mn |
| Sep 30, 2021 | -8.47 Mn |
| Jun 30, 2021 | -10.46 Mn |